Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811815 | 0.90 | ACHE (0.41) | AAK1ACHEBCHELMNAHTT | |
| SCHEMBL12015804 | 0.89 | CYP2C9 (0.43) | AAK1ACHEBCHELMNAHTT | |
| SCHEMBL11951589 | 0.87 | ACHE (0.43) | AAK1ACHEBCHELMNAHTT | |
| SCHEMBL17812425 | 0.86 | ACHE (0.39) | AAK1ACHEKEAP1NFE2L2BCHE | |
| SCHEMBL17811834 | 0.84 | HTT (0.37) | AAK1ACHEBCHELMNAHTT | |
| SCHEMBL13450831 | 0.84 | VDR (0.52) | AAK1ACHEKEAP1NFE2L2BCHE | |
| SCHEMBL11951605 | 0.83 | FDPS (0.40) | ACHEKEAP1NFE2L2BCHESMN1; SMN2 | |
| SCHEMBL20820537 | 0.83 | AAK1 (0.45) | AAK1 | |
| SCHEMBL17811806 | 0.83 | MRGPRX4 (0.39) | AAK1ACHEKEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL12015792 | 0.80 | PDE2A (0.43) | ACHEBCHELMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | AAK1 457/4885ACHE 268/4885KEAP1 1393/4885 |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | AAK1 457/4885ACHE 268/4885KEAP1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.